People with end-stage age-related macular degeneration (AMD) have improved visual acuity and quality of life after receiving an intraocular implant containing a tiny telescope in 1 eye, new research shows. An ophthalmologist who participated in the c…
Author: Eyewire Today
Statement from AAO regarding “Poppers” and Potential Retinal Damage
A letter by French ophthalmologists, published in the October 14, 2010 issue of the New England Journal of Medicine, described eye and vision damage related to the use of poppers The American Academy of Ophthalmology urges the public to avoid the use…
Anorexia Nervosa May Cause Serious Harm to Patients’ Eyes
The eating disorder anorexia nervosa (AN) can lead to eye damage, possibly of a serious nature, according to an article published online October 20 in the British Journal of Ophthalmology. As many as 3% of middle- and upper-class women, the majority …
Report on Global Ophthalmology Drug and Devices Market
Global ophthalmology drug and devices market is witnessing a significant growth due to the increasing incidence and prevalence of eye related disorders such as presbyopia, macular degeneration, and diabetic retinopathy among the aging population. Wit…
Synexus Sets Its Sights on Ophthalmology
Synexus is set to take part in a number of global ophthalmology trials following recent investment in clinical research expertise and technology in this area. Chief Executive, Dr Christophe Berthoux says that ophthalmology offers considerable growth …
Novartis’ Vasella elected chairman at Alcon
Novartis’ chairman Daniel Vasella was elected board chairman of Alcon, increasing the Swiss drugmaker’s grip of the U.S. eyecare company as it tries to buy the stake it does not already own. Alcon’s Independent Director’s Committee (IDC), which has r…
Xalatan Receives Paediatric Indication In Europe
Pfizer announced that Xalatan 0.005% (latanoprost) has been approved by the European Commission for reduction of elevated intraocular pressure (IOP) in the treatment of paediatric patients with elevated intraocular pressure and paediatric glaucoma. L…
Time is on Novartis Side in Alcon Bid
Novartiss bet that with time it would win over Alcon Inc.s shareholders seems to be paying off. Since the Swiss pharma giant bought a majority stake in the eye-care firm earlier this year, resistance from Alcons minority shareholders to Novartiss off…
Garamycin Ophthalmic Ointment Now Available from Fera Pharmaceuticals
Fera Pharmaceuticals announced the launch today of preservative free Garamycin (gentamicin sulfate) Ophthalmic Ointment USP. Providing an alternate gentamicin formulation, without preservatives, was an unmet need Fera was glad to fill. When Erythromy…
AAO Joint Meeting Marked by Academy Firsts and Strong Turnout
Academy firsts and strong turnout marked the largest and most comprehensive ophthalmic educational meeting in the world. The American Academy of Ophthalmologys (Academy) 2010 Joint Meeting in conjunction with the Middle East Africa Council of Ophthal…
New Clinical Data On Meriva Show Eye Inflammations Reduction
A new clinical study published in Clinical Ophthalmology shows that Meriva, an Indena proprietary complex of curcumin with soy phosphatidylcholine, can play an important role in the adjunctive therapy of recurrent anterior uveitis (RAU), the most com…
Novartis Third-Quarter Net Rises on Lucentis, Exforge
Novartis AG indicated Alcon Inc. shareholders should take another look at its $11.5 billion buyout offer now that an increase in the Swiss drugmakers share price and a rally in the franc have lifted the value of the bid. Novartis, which owns 77 perce…
Alcon 3Q profit falls on Novartis deal costs
Alcon Inc., which makes treatments for glaucoma and eye infections, said Wednesday its third-quarter net income fell 13 percent on costs related to its majority takeover by fellow Swiss drugmaker Novartis SA. Still the results topped analysts’ expect…
Abbott’s 3Q drug sales up 22 percent, net income drops on restructuring, recall costs
Abbott Laboratories, a maker of drugs and medical devices, fell after it reported third-quarter sales that missed analysts estimates. The shares dropped 45 cents, or less than 1 percent, to $52.42 at 4:03 p.m. in New York Stock Exchange composite tra…